152781-30-1Relevant articles and documents
Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders
Mastromarino, Margherita,Favia, Maria,Schepetkin, Igor A.,Kirpotina, Lylia N.,Trojan, Ewa,Niso, Mauro,Carrieri, Antonio,Le?kiewicz, Monika,Regulska, Magdalena,Darida, Massimiliano,Rossignolo, Francesco,Fontana, Stefano,Quinn, Mark T.,Basta-Kaim, Agnieszka,Leopoldo, Marcello,Lacivita, Enza
, p. 5004 - 5028 (2022/03/27)
Formyl peptide receptor 2 (FPR2) agonists can boost the resolution of inflammation and can offer alternative approaches for the treatment of pathologies with underlying chronic neuroinflammation, including neurodegenerative disorders. Starting from the FPR2 agonist 2 previously identified in our laboratory and through fine-tuning of FPR2 potency and metabolic stability, we have identified a new series of ureidopropanamide derivatives endowed with a balanced combination of such properties. Computational studies provided insights into the key interactions of the new compounds for FPR2 activation. In mouse microglial N9 cells and in rat primary microglial cells stimulated with lipopolysaccharide, selected compounds inhibited the production of pro-inflammatory cytokines, counterbalanced the changes in mitochondrial function, and inhibited caspase-3 activity. Among the new agonists, (S)-11l stands out also for the ability to permeate the blood-brain barrier and to accumulate in the mouse brain in vivo, thus representing a valuable pharmacological tool for studies in vivo.
